CBIO

Conviction 82HealthcareScan · Fri, Jun 26, 2026

Bullish belt hold

CBIO$18.49+8.83%

ResistanceSupportVol 14

Vol MA14 223.74K

Mar 27Apr 15May 4May 20Jun 9Jun 26

CRESCENT BIOPHARMA, INC.PHARMACEUTICAL PREPARATIONSwww.crescentbiopharma.com ↗

Price18.49

Change+8.83%

Gap+0.41%

Rel volume2.45×

Avg volume245.51K

Avg $ vol4.47M

SMA 2018.04

SMA 5019.68

SMA 20014.39

Price vs 50-6.04%

Price vs 200+28.47%

MA stackmixed

50/200 cross—

Supertrenddown · 21.63

RSI (14)51

MACD hist0.01

MACD crossbull · 0d

Stoch %K / %D76 / 38

ADX (14)10

+DI / −DI17 / 16

RSI divergence—

MACD divergence—

ATR %+8.40%

ADR %8.06%

52w high26.98

52w low8.94

From 52w high-31.47%

Above 52w low+106.82%

New 52w highNo

SqueezeOn · 2d

Bollinger width18.71%

%B0.63

Donchian pos32.72%

Donchian high22.52

Donchian low16.53

AVWAP (52w high)19.68

vs AVWAP high-6.07%

AVWAP (52w low)17.27

vs AVWAP low+7.05%

OBV trendDown

Chaikin MF (20)-0.09

Today vs 20d2.45×

Avg vol (14d)223.74K

Avg vol (20d)245.51K

Avg $ vol (20d)4.47M

Market cap—

RS 3m (vs SPY)+32.43%

RS 6m (vs SPY)+29.24%

RS line new highNo

Trend template6/8

Technical rank66.6

1 week+4.52%

1 month-11.06%

3 months+36.96%

6 months+52.56%

1 year+2.72%

YTD+66.88%

P/E-3.03

P/B2.54

P/S43.07

P/FCF-6.45

EPS-0.5900

Div yield—

ROE-83.73%

ROA-77.31%

Debt/Eq—

Current13.78

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth-306.40%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value277.91M

Revenue1.04M

Net income-23.28M

Gross profit—

Free cash flow-72.45M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out—

Employees44

ListedMon, Jun 16, 2025

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeA

Conviction82 / 100

Pattern quality—

Tech rank66.6 / 100

Group rank50 / 100

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmBullish belt hold

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in CBIO

All disclosures →

No recent disclosed trades by Congress in CBIO. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in CBIO · 8 buys

Insider	Side	Shares	Value	Traded	Filed
Violin Jonathan Director · Stock Option (Right to Buy) · 2026-06-02	Grant	11.05K	$0	2026-06-02	2026-06-03
Moran Susan Director · Stock Option (Right to Buy) · 2026-06-02	Grant	11.05K	$0	2026-06-02	2026-06-03
Fairmount Healthcare Fund II L.P. Director · Stock Option (Right to Buy) · 2026-06-02	Grant	11.05K	$0	2026-06-02	2026-06-03
Fairmount Funds Management LLC Director · Stock Option (Right to Buy) · 2026-06-02	Grant	11.05K	$0	2026-06-02	2026-06-03
Lubner David Charles Director · Stock Option (Right to Buy) · 2026-06-02	Grant	11.05K	$0	2026-06-02	2026-06-03
Harwin Peter Evan Director · Stock Option (Right to Buy) · 2026-06-02	Grant	11.05K	$0	2026-06-02	2026-06-03
Kiselak Tomas Director · Stock Option (Right to Buy) · 2026-06-02	Grant	11.05K	$0	2026-06-02	2026-06-03
Balcom Alexandra Director · Stock Option (Right to Buy) · 2026-06-02	Grant	11.05K	$0	2026-06-02	2026-06-03

SEC filings

EDGAR filings in CBIO · 3 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.